Skip to main content
Funded Studies

Antisense Oligonucleotides as Drug Candidates for Alpha-Synuclein-Linked Diseases

Study Rationale:
The goal of this project is to find drugs that target alpha-synuclein, a key protein in Parkinson's disease (PD). We will design and test second-generation antisense oligonucleotides (ASOs), man-made molecules that destroy mRNA, the template from which a protein is built. Treatment with ASO molecules is expected to decrease the production of alpha-synuclein in the long term and prevent its abnormal buildup and spreading in PD.

We hypothesize that by directly and chronically modifying the alpha-synuclein mRNA, we can decrease the buildup of alpha-synuclein in people with PD in the long term.

Study Design:
We will design and develop ASOs that modify the production of alpha-synuclein mRNA to make it least able to serve as a template for the protein. Initially, the validity and functionality of the designed ASOs will be tested in human cells that produce alpha-synuclein. The most efficient ASOs will then be tested in pre-clinical models to assess the reduction of alpha-synuclein levels in these models.

Impact on Diagnosis/Treatment of Parkinson's disease:
This study is designed to provide a proof that ASOs can be used to treat diseases linked to alpha-synuclein.

Next Steps for Development:
Following successful completion of the study, we will conduct further pre-clinical studies required to safely assess ASOs' potential for becoming candidate drugs for Parkinson's disease.


  • Epaminondas Doxakis, PhD, MBA

    Athens Greece

Discover More Grants

Search by Related Keywords

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.